CotrimoxazoleThird Party Manufacturing in India

Cotrimoxazole works by blocking two consecutive steps in the biosynthesis of nucleic acids and proteins in bacteria. Sulfamethoxazole inhibits the synthesis of dihydrofolic acid, while trimethoprim blocks dihydrofolate reductase. It binds to these critical bacterial enzymes to help the body eradicate broad-spectrum bacterial infections. Unlike single-agent antifolates, its sequential block produces a synergistic bactericidal effect. It is highly effective and well-tolerated.

Therapeutic Uses

• Pneumocystis Pneumonia: It serves as first-line therapy for both prophylaxis and active treatment of Pneumocystis jirovecii infections.
• Urinary Tract Infections: It manages acute uncomplicated urinary tract blockages caused by susceptible E. coli strains.
• Otitis Media: It resolves pediatric middle ear bacterial manifestations when first-line choices are restricted.

Why Manufacturers Choose Cotrimoxazole

This essential generic medicine continues to command high volume parameters across rural and urban markets. Sourcing Cotrimoxazole third party manufacturing in India gives companies access to an affordable, globally required antimicrobial asset. Our partner facilities maintain strict laboratory oversight where our production facilities are WHO-GMP certified, ensuring high quality control for CAS number 8064-90-2.